by MASA | Apr 15, 2026 | Asthma, Drug Updates, News, Patient Resources, Severe Asthma, Type 2 Inflammation
In an interview on The Valder Beebe Show, Dr. Siri discusses the clinical and patient experience aspects of severe asthma. Over two millions Americans of various ages live with severe asthma out of 20-30 million people with asthma. From 0:30 to 3:55, Dr. Siri...
by MASA | Dec 19, 2024 | Drug Updates
The U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, for the treatment of mild, moderate, or severe atopic dermatitis (AD) in adults and children aged 2 years and older. This approval expands the use of VTAMA, previously approved for...
by MASA | Dec 15, 2024 | Drug Updates
FDA approved Epinephrine nasal spray (neffy) for emergency treatment of allergic reaction type 1 in August in adults and pediatric patients who weigh at least 30 kg (or around 66 lbs). Neffy provides an option to treat anaphylaxis that does not involve injection,...
by MASA | Aug 15, 2024 | Drug Updates, Patient Resources, Rare Diseases
What is D.R.E.S.S.? Drug Reaction with Eosinophilia and Systemic Symptoms (D.R.E.S.S.) is a type of drug allergy which can occur as a reaction to a large variety of medications. Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver...
by MASA | Jul 31, 2024 | Drug Updates
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
by MASA | Apr 23, 2024 | Drug Updates, News
The U.S. Food and Drug Administration (FDA) has provided an emergency use authorization (EUA) for a new medicine called Pemgarda™ (pemivibart), aimed at preventing COVID-19 in certain high-risk individuals. This medication is specifically designed for those who are...
